Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Adipose tissue plays essential roles in maintaining lipid and glucose homeostasis. To date
several types of adipose tissue have been identified, namely white, brown, and beige, that …

Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

In the last few years, a great interest has emerged in investigating the pleiotropic effects of
Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower …

The cardiovascular complications contribute to a majority of diabetes associated morbidity
and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

Diabetes, one of the most prevalent chronic diseases in the world, is strongly associated
with a poor prognosis in COVID-19. Scrupulous blood sugar management is crucial, since …

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …